Esophageal squamous cell carcinoma

This trial tests an artificial intelligence system called ADTPS that helps doctors remove early-stage esophageal cancer or precancerous lesions using a scope. The AI analyzes live images during the procedure and overlays a suggested cutting path on the screen. Half of the partici…

This early-phase trial tests a freezing treatment called cryotherapy, given before and during standard chemoradiation, for people with locally advanced esophageal cancer. The main goal is to find the safest number of cryotherapy sessions. Researchers will also check if the freezi…

Researchers are testing whether adding the immunotherapy drug camrelizumab to chemotherapy or chemoradiotherapy before surgery helps people with locally advanced esophageal squamous cell carcinoma. The trial enrolls adults with resectable tumors who have not received prior treatm…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study tests whether adding the drug cixutumumab to standard chemotherapy (paclitaxel) can help people with advanced esophageal or stomach-junction cancer live longer without their cancer growing. About 94 adults whose cancer has spread and who have already tried one treatmen…

This early-phase trial tests whether adding a cancer-killing virus called OBP-301 to standard chemotherapy and radiation is safe for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. The virus is designed to infect and destroy tumor cells. Sixtee…

This study tests a new drug called futibatinib combined with standard immunotherapy and chemotherapy in people with advanced esophageal or pancreatic cancer. The goal is to see if the combination can shrink tumors and control the disease. About 53 adults who have not had prior tr…

This study compares two radiation techniques for people with stage I to IVA esophageal cancer: proton beam therapy (which uses protons) and intensity modulated photon radiotherapy (which uses X-rays). The goal is to see which one works better at helping people live longer and cau…

This early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…

This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …

This phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced esophageal cancer that has worsened after initial treatment. About 497 participants will receive either the new drug or one of several chemotherapies. The goal is to see if …

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This phase II trial tests a personalized strategy for people with resectable esophageal squamous cell carcinoma. Participants first receive a combination of chemotherapy and the immunotherapy drug sugemalimab. Those whose tumors shrink significantly then get radiation plus more i…

This phase 2 trial tests whether combining the immunotherapy drug cardenilimab with standard chemotherapy can shrink locally advanced esophageal cancer that cannot be surgically removed at first. The goal is to turn these tumors into operable ones, potentially improving survival.…

This phase 2 trial explores whether adding low-dose radiotherapy and an immunotherapy drug (retlirafusp alfa) to standard chemotherapy before surgery can improve outcomes for people with a type of esophageal cancer that has spread locally but can still be removed. The study enrol…

This early-phase trial tests whether giving chemoradiation plus the immunotherapy drug pembrolizumab, followed by pembrolizumab and lenvatinib before surgery, can kill more cancer cells in people with esophageal or gastroesophageal junction cancer that hasn't spread. The study in…

This early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…

This study tests whether a PD-1 inhibitor (INCMGA00012) can help prevent esophageal cancer from returning after standard chemoradiation. About 110 adults with locally advanced esophageal squamous cell carcinoma who completed chemoradiation without progression will be randomly ass…

This phase 2 trial tests whether giving the immune checkpoint inhibitor IMC-001 before surgery can shrink tumors in people with resectable gastric, esophageal, or liver cancer. About 48 participants will receive two cycles of the drug, then undergo surgery. The main goal is to se…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemoradiation helps people with advanced esophageal cancer that cannot be removed by surgery. About 640 participants will receive either durvalumab or a placebo alongside their cancer treatment…

This phase II trial tests whether adding an immunotherapy drug (sintilimab) and immune-supporting agents to a medium-dose chemo-radiation regimen can improve outcomes for people with advanced esophageal cancer. About 50 participants will receive the combination, along with probio…

This study tests a new drug called cadonilimab, combined with chemotherapy and radiation, for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if this combination can better control the cancer and prevent it from coming back. About 46 p…

This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before and after surgery helps people with a certain type of advanced esophageal cancer. About 663 participants will receive either toripalimab plus chemo or a placebo plus chemo. The goal…

This early-phase trial tests two experimental vaccines (ChAdOx1 and MVA) designed to help the immune system target cancer proteins MAGE-A3 and NY-ESO-1. About 15 adults with advanced non-small cell lung cancer or squamous esophageal cancer will receive the vaccines alongside thei…

This early-phase trial tests whether combining two drugs—camrelizumab (an immunotherapy) and palbociclib (a targeted therapy)—is safe and feasible when given before surgery for esophageal cancer. Six adults with resectable esophageal squamous cell carcinoma will receive the drugs…

This study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.

This early-stage trial aimed to test a new drug called S095033 combined with the chemotherapy paclitaxel in people with advanced or metastatic esophageal squamous cell carcinoma. The goal was to check safety, tolerability, and signs of tumor shrinkage. However, the study was with…

This early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…

This study tests a new treatment plan for people with advanced esophageal cancer that cannot be surgically removed. Participants first receive immunotherapy plus chemotherapy, followed by chemoradiation. The goal is to see if this approach improves survival and controls the disea…

This phase 2 trial tests whether combining two immune-boosting drugs (ipromlimab and tuvonralimab) with standard chemotherapy before surgery can help shrink tumors in people with locally advanced esophageal cancer. The study involves 62 participants and is currently active but no…

This study looks at whether a blood test that finds tiny traces of cancer DNA (called ctDNA-MRD) can help doctors decide who needs more treatment after standard chemoradiation for advanced esophageal cancer. About 65 people with unresectable cancer will get extra immunotherapy an…

This study tests adding two drugs, nivolumab and cetuximab, to standard chemoradiation for people with a type of esophageal cancer that hasn't spread far. The goal is to see if this combination can make tumors disappear before surgery. The study involves 12 adults who haven't had…

This phase II trial tests whether adding two targeted drugs (nimotuzumab and camrelizumab) to standard chemotherapy before surgery can improve outcomes for people with locally advanced esophageal cancer. About 48 participants will be randomly assigned to receive the combination o…

This phase 3 trial tests whether adding immunotherapy (sintilimab) and chemotherapy before standard chemoradiotherapy helps people with inoperable esophageal cancer live longer and reduces the chance of the cancer coming back. About 242 adults aged 18-75 with stage 2-4 esophageal…

This study tests whether adding the drug serplulimab to standard chemotherapy before surgery can help people with a certain type of esophageal cancer. The goal is to shrink tumors more effectively and lower the chance of cancer coming back. About 48 adults with stage II to IVA es…

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This phase 2 study tests whether adding the immunotherapy drug tislelizumab to chemotherapy after standard chemoradiation can improve outcomes for people with locally advanced esophageal cancer who are at high risk. About 80 participants will receive the combination before surger…

This early-phase study tests whether combining the immunotherapy drug camrelizumab with standard radiation before surgery can help shrink tumors in people with esophageal cancer. About 25 patients will receive the combination, then undergo surgery 4-8 weeks later. Researchers wil…

This study tests a drug called sacituzumab govitecan in 53 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug can shrink tumors. Researchers will also track how long any response lasts and how well the drug contro…

This study tests a combination of two drugs, SI-B001 and irinotecan, in people with advanced esophageal cancer that has come back or spread. The goal is to see if the combo can shrink tumors and control the disease. About 22 adults who have already tried standard treatments are t…

This Phase 2 trial tests whether adding an experimental immunotherapy drug (SHR-8068) to a standard immunotherapy (adebrelimab) plus chemotherapy can shrink tumors better than standard treatment alone in people with advanced stomach or esophageal cancer. About 153 participants wi…

This early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it …

This trial tests whether a new AI-driven biomarker, called the Microbial-Sensory Coupling (MSC) index, can predict how well patients with esophageal squamous cell carcinoma respond to anti-PD-1 immunotherapy. The biomarker measures the spatial relationship between a specific bact…

This study looks at whether artificial intelligence can accurately determine the depth of early esophageal cancer from endoscopic images. Researchers will review past records and images from 890 patients who had their tumors removed. The goal is to see if AI can help doctors deci…

This study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…

This study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …

This study is testing whether an artificial intelligence (AI) model can help doctors better detect, diagnose, and treat esophageal cancer. Researchers will feed de-identified data from 12,000 patients receiving routine care into the AI and compare its recommendations to standard …

This research study looks at how certain cancers (head and neck, esophagus, and anal canal) change at the genetic and immune level when patients receive chemotherapy or immunotherapy. About 39 people with advanced cancer will provide blood samples and tumor tissue over time. The …

This study examines whether certain proteins and immune signals in the blood and tumor tissue can predict if esophageal squamous cell carcinoma will come back after treatment. Researchers will collect blood and biopsy samples from 120 adults at diagnosis and during early treatmen…

This study collects blood and tissue samples from 1,000 adults with Barrett's esophagus or esophageal cancer during their routine endoscopy. The goal is to build a biorepository that links clinical data with specimens, enabling future research into these conditions. Participants …

This study looks at tissue samples from 30 people with esophageal squamous cell carcinoma to see how far the cancer spreads beyond what the surgeon can see. Researchers want to find patterns of hidden tumor growth to help guide future surgeries. Participants have already had thei…

This study observes 208 adults in France with advanced or metastatic stomach, esophageal, or gastroesophageal junction cancer who are receiving nivolumab combined with chemotherapy as their first treatment. Researchers will track how long patients live and how their disease progr…

This study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make…

This observational study collects blood and tumor tissue samples from people with gastroesophageal cancer to study genetic changes that may cause resistance to immunotherapy. It does not involve any treatment or experimental drugs. The goal is to identify new targets for future i…